Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

SK Chemicals, TheraVida deal

April 8, 2013 7:00 AM UTC

TheraVida granted SK Chemicals exclusive rights to develop and commercialize Tolenix ( THVD-201) and THVD-202 in South Korea for overactive bladder (OAB) and urge urinary incontinence. SK Chemicals is responsible for funding the development and commercialization of the compounds, and TheraVida is eligible for milestones upon the submission of an NDA and first sale in South Korea, plus tiered, double-digit royalties. TheraVida declined to disclose details, and SK Chemicals could not be reached for details. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article